Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure

British Journal of Haematology

Volumn 157, Issue 6, 2012, Pages 764-766

  Prébet, Thomas ^a,b,c   Gore, Steven D ^a,c   Thépot, Sylvain ^c   Esterni, Benjamin ^b   Quesnel, Bruno ^c   Beyne Rauzy, Odile ^c   Dreyfus, François ^c   Gardin, Claude ^c   Fenaux, Pierre ^c   Vey, Norbert ^b,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b INSTITUT PAOLI CALMETTES   (France)

^c Groupe Francophone des Myelodysplasies   (France)

Author keywords

Acute myeloid leukaemia; Azacitidine; Myelodysplasia; Outcome; Relapse

Indexed keywords

AZACITIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE DURATION; DRUG TREATMENT FAILURE; FEMALE; HIGH RISK PATIENT; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL TIME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84861532017     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09076.x     Document Type: Letter

References (10)

1. Bello, C., Yu, D., Komrokji, R.S., Zhu, W., Wetzstein, G.A., List, A.F. & Lancet, J.E. (2011) Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer, 117, 1463-1469.
2. Cheson, B.D., Bennett, J.M., Kopecky, K.J., Buchner, T., Willman, C.L., Estey, E.H., Schiffer, C.A., Doehner, H., Tallman, M.S., Lister, T.A., Lo-Coco, F., Willemze, R., Biondi, A., Hiddemann, W., Larson, R.A., Lowenberg, B., Sanz, M.A., Head, D.R., Ohno, R. & Bloomfield, C.D. (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology, 21, 4642-4649.
3. Fandy, T.E., Herman, J.G., Kerns, P., Jiemjit, A., Sugar, E.A., Choi, S.H., Yang, A.S., Aucott, T., Dauses, T., Odchimar-Reissig, R., Licht, J., McConnell, M.J., Nasrallah, C., Kim, M.K., Zhang, W., Sun, Y., Murgo, A., Espinoza-Delgado, I., Oteiza, K., Owoeye, I., Silverman, L.R., Gore, S.D. & Carraway, H.E. (2009) Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood, 114, 2764-2773.
4. Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., Gore, S.D., Seymour, J.F., Bennett, J.M., Byrd, J., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C. & Silverman, L.R. (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol, 10, 223-232.
5. Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A.F., Gore, S., Seymour, J.F., Dombret, H., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C.L. & Silverman, L.R. (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. Journal of Clinical Oncology, 28, 562-569.
6. Gore, S.D., Baylin, S., Sugar, E., Carraway, H., Miller, C.B., Carducci, M., Grever, M., Galm, O., Dauses, T., Karp, J.E., Rudek, M.A., Zhao, M., Smith, B.D., Manning, J., Jiemjit, A., Dover, G., Mays, A., Zwiebel, J., Murgo, A., Weng, L.J. & Herman, J.G. (2006) Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Research, 66, 6361-6369.
7. Itzykson, R., Thepot, S., Quesnel, B., Dreyfus, F., Beyne-Rauzy, O., Turlure, P., Vey, N., Recher, C., Dartigeas, C., Legros, L., Delaunay, J., Salanoubat, C., Visanica, S., Stamatoullas, A., Isnard, F., Marfaing-Koka, A., de, B.S., Chelghoum, Y., Taksin, A.L., Plantier, I., Ame, S., Boehrer, S., Gardin, C., Beach, C.L., Ades, L. & Fenaux, P. (2011) Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood, 117, 403-411.
8. Jiang, Y., Dunbar, A., Gondek, L.P., Mohan, S., Rataul, M., O'Keefe, C., Sekeres, M., Saunthararajah, Y. & Maciejewski, J.P. (2009) Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood, 113, 1315-1325.
9. Nimer, S.D. (2008) Myelodysplastic syndromes. Blood, 111, 4841-4851.
10. Prebet, T., Gore, S.D., Esterni, B., Gardin, C., Itzykson, R., Thepot, S., Dreyfus, F., Beyne-Rauzy, O., Recher, C., Ades, L., Quesnel, B., Beach, C.L., Fenaux, P. & Vey, N. (2011) Outcome of high risk myelodysplastic syndrome after azacitidine treatment failure. Journal of Clinical Oncology, 29, 3322-3327.